TLDR
- Codexis (CDXS) exceeded Q4 EPS projections by $0.10, delivering $0.11 versus analyst expectations of $0.01
- Fourth-quarter revenue reached $38.9 million, an 81% year-over-year increase, surpassing the $35.83 million forecast
- A major $37.8 million Technology Transfer Agreement with Merck powered the quarterly revenue jump
- 2025 full-year net loss improved to $44.0 million from $65.3 million recorded in 2024
- Company projects 2026 revenue between $72–$76 million; sufficient cash reserves through 2027
Codexis unveiled its fourth-quarter and full-year 2025 financial performance on March 11, 2026, exceeding analyst projections across key metrics. Shares rose 2.4% to reach $1.27 following the announcement.
The company posted fourth-quarter earnings per share of $0.11, crushing consensus forecasts of $0.01 by $0.10. Quarterly revenue totaled $38.9 million, outperforming the Street estimate of $35.83 million and representing an 81% increase compared to Q4 2024’s $21.5 million.
The revenue explosion stemmed primarily from a $37.8 million Technology Transfer Agreement finalized with Merck during the fourth quarter. This substantial transaction fundamentally altered the quarter’s financial profile.
Across the entire fiscal year, aggregate revenue climbed 19% to $70.4 million versus $59.3 million in the previous year. Product gross margin expanded to 64%, up from 56% recorded in 2024.
The annual net loss contracted to $44.0 million, translating to $0.50 per diluted share, a notable improvement from the $65.3 million loss ($0.89 per share) reported in 2024. The fourth quarter turned profitable with net income of $9.6 million, contrasting sharply with the $10.4 million loss in the year-ago period.
Selling, general and administrative expenses decreased to $47.1 million for the year from $55.1 million in 2024, reflecting reduced stock-based compensation and lower legal fees. Research and development investments increased to $52.3 million from $46.3 million.
The fiscal year also absorbed $3.4 million in non-recurring restructuring expenses linked to a workforce reduction implemented in November 2025.
Cash Position and Guidance
Codexis concluded 2025 holding $78.2 million in cash, cash equivalents and short-term investments. Management indicates this balance provides operating capital through the conclusion of 2027.
Looking ahead to 2026, the company projects total revenues ranging from $72 million to $76 million.
Operationally, Codexis reports active engagement with more than 40 companies spanning 55 prospective opportunities. CEO Alison Moore highlighted that client dialogues have evolved from preliminary feasibility assessments toward substantive contract negotiations.
The organization secured a lease agreement for a GMP-compliant facility supporting kilogram-scale production. Facility retrofit construction is slated to commence during the second half of 2026, with complete production capabilities anticipated by year-end 2027.
Codexis also finalized an arrangement with Axolabs—marking its third CDMO collaboration—to assess its ECO Synthesis platform at Axolabs’ production facilities.
Analyst Sentiment and Institutional Activity
Notwithstanding the earnings outperformance, Wall Street analyst sentiment leans negative. Weiss Ratings maintained a “Sell” rating on January 21, and MarketBeat’s aggregate analyst consensus similarly reflects a “Sell” recommendation.
Shares currently trade nearer to the 52-week low of $0.96 than the high of $3.87, with the company carrying a market capitalization of $114.7 million. The 50-day moving average stands at $1.39, while the 200-day average rests at $1.90.
Institutional investors have demonstrated increased interest. Millennium Management expanded its holdings by 3,376.5% during Q3. Renaissance Technologies boosted its position by 137.5% in Q4. Institutional ownership now represents 78.54% of outstanding shares.
The company targets securing a licensing agreement with a major pharmaceutical partner during the latter half of 2026 and intends to present stereoisomer control research findings at the 2026 TIDES USA annual conference.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
